Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution

Hardman & Co Research on Shield Therapeutics (STX):

Focusing on successful execution

Shield is a commercial-stage pharma company delivering specialty products that address the unmet medical need of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the differentiating characteristics of ACCRUFeR® as an oral ID drug, in order to generate sales traction. 1H’24 results have confirmed that sales continue to progress well, while costs have been closely controlled. Management is focused on successful execution and reaffirmed its view that the gross cash position coupled with expected growth will be sufficient to see Shield through to cashflow-breakeven in 2H’25.

Please click on the link below for the full report:

https://hardmanandco.com/research/corporate-research/focusing-on-successful-execution/

If you are interested in meeting the company, you can register your interest by clicking on the above link.

Hardman & Co Research can be accessed for free under MiFID. Please click here to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.